Literature DB >> 24657538

The evolution of the unstable cancer genome.

Rebecca A Burrell1, Charles Swanton2.   

Abstract

Cancer next-generation sequencing and genomics studies published over the last five years have provided unprecedented insights into the forces shaping cancer genome evolution. In particular, these studies have revealed a high level of heterogeneity not only between different tumours, but also within individual tumours; the 'cancer genome' may evolve along several independent trajectories within a single tumour. There is an increasing appreciation of the importance of intratumour genetic heterogeneity in determining disease progression and clinical outcome in cancer medicine, and thus an increasing awareness of the need to understand the processes that both generate genetic diversity and shape genome evolution in human tumours.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 24657538     DOI: 10.1016/j.gde.2013.11.011

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  28 in total

Review 1.  Hypermutation in human cancer genomes: footprints and mechanisms.

Authors:  Steven A Roberts; Dmitry A Gordenin
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

Review 2.  A population genetics perspective on the determinants of intra-tumor heterogeneity.

Authors:  Zheng Hu; Ruping Sun; Christina Curtis
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-03-06       Impact factor: 10.680

3.  In silico analysis of DNA re-replication across a complete genome reveals cell-to-cell heterogeneity and genome plasticity.

Authors:  Maria Anna Rapsomaniki; Stella Maxouri; Patroula Nathanailidou; Manuel Ramirez Garrastacho; Nickolaos Nikiforos Giakoumakis; Stavros Taraviras; John Lygeros; Zoi Lygerou
Journal:  NAR Genom Bioinform       Date:  2021-01-28

4.  Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.

Authors:  Chiara Ambrogio; Gonzalo Gómez-López; Mattia Falcone; August Vidal; Ernest Nadal; Nicola Crosetto; Rafael B Blasco; Pablo J Fernández-Marcos; Montserrat Sánchez-Céspedes; Xiaomei Ren; Zhen Wang; Ke Ding; Manuel Hidalgo; Manuel Serrano; Alberto Villanueva; David Santamaría; Mariano Barbacid
Journal:  Nat Med       Date:  2016-02-08       Impact factor: 53.440

Review 5.  Turning the headlights on novel cancer biomarkers: Inspection of mechanics underlying intratumor heterogeneity.

Authors:  Michelle McBride; Padmashree C G Rida; Ritu Aneja
Journal:  Mol Aspects Med       Date:  2015-05-27

6.  Single-cell genetic analysis of clonal dynamics in colorectal adenomas indicates CDX2 gain as a predictor of recurrence.

Authors:  David Fiedler; Kerstin Heselmeyer-Haddad; Daniela Hirsch; Leanora S Hernandez; Irianna Torres; Darawalee Wangsa; Yue Hu; Luis Zapata; Josef Rueschoff; Sebastian Belle; Thomas Ried; Timo Gaiser
Journal:  Int J Cancer       Date:  2018-12-11       Impact factor: 7.396

Review 7.  Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?

Authors:  Jiri Polivka; Martin Pesta; Filip Janku
Journal:  Expert Rev Mol Diagn       Date:  2015-11-11       Impact factor: 5.225

Review 8.  Poised epigenetic states and acquired drug resistance in cancer.

Authors:  Robert Brown; Edward Curry; Luca Magnani; Charlotte S Wilhelm-Benartzi; Jane Borley
Journal:  Nat Rev Cancer       Date:  2014-09-25       Impact factor: 60.716

Review 9.  Structural variation discovery in the cancer genome using next generation sequencing: computational solutions and perspectives.

Authors:  Biao Liu; Jeffrey M Conroy; Carl D Morrison; Adekunle O Odunsi; Maochun Qin; Lei Wei; Donald L Trump; Candace S Johnson; Song Liu; Jianmin Wang
Journal:  Oncotarget       Date:  2015-03-20

Review 10.  Tumour heterogeneity and the evolution of polyclonal drug resistance.

Authors:  Rebecca A Burrell; Charles Swanton
Journal:  Mol Oncol       Date:  2014-07-10       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.